CD274 and neoplasm: The correlation of lesion 18F-BMS-986192 SUV with PD-L1 expression and lesion 89Zr-nivolumab SUV with PD-1+ lymphoid aggregates may also be useful to study drug induced changes in the tumor microenvironment in immunotherapy combination trials.